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Abstract
New molecular identification techniques and the increased number of patients with various immune defects or underlying
conditions lead to the emergence and/or the description of novel species of human and animal fungal opportunistic
pathogens. Antifungal susceptibility provides important information for ecological, epidemiological and therapeutic issues.
The aim of this study was to assess the potential risk of the various species based on their antifungal drug resistance,
keeping in mind the methodological limitations. Antifungal susceptibility profiles to the five classes of antifungal drugs
(polyens, azoles, echinocandins, allylamines and antimetabolites) were determined for 1698 yeast reference strains
belonging to 992 species (634 Ascomycetes and 358 Basidiomycetes). Interestingly, geometric mean minimum inhibitory
concentrations (MICs) of all antifungal drugs tested were significantly higher for Basidiomycetes compared to Ascomycetes
(p,0.001). Twenty four strains belonging to 23 species of which 19 were Basidiomycetes seem to be intrinsically ‘‘resistant’’
to all drugs. Comparison of the antifungal susceptibility profiles of the 4240 clinical isolates and the 315 reference strains
belonging to 53 shared species showed similar results. Even in the absence of demonstrated in vitro/in vivo correlation,
knowing the in vitro susceptibility to systemic antifungal agents and the putative intrinsic resistance of yeast species present
in the environment is important because they could become opportunistic pathogens.
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Introduction
Among the estimated 1.5 million fungal species, approximately
200 species of yeasts and moulds associated with humans as
commensals or pathogens are reported, according to the
Colloquium of the American Academy of Microbiology on the
fungal Kingdom (The Fungal Kingdom: Diverse and Essential
Roles in Earth’s Ecosystem, June 2008, ASM http://academy.
asm.org/). The number of yeasts species has increased over time.
In 1928, Guillermond described only 22 genera of yeasts, and the
successive editions of one textbook on yeasts included 349 species
belonging to 39 genera in 1970 [1], more than 700 species
belonging to 100 different genera in 1998 [2], and 11 new genera
since 2003 [3,4]. In the fifth edition of the reference yeast book
published by Kurtzman et al. [5], 149 genera and nearly 1500
species are described. Furthermore, new yeast species are regularly
recognized as opportunistic pathogens. This can be explained by
an increased awareness of invasive fungal infections and by
improved techniques that allow better identification of fungal
species based on polygenic analyses. There is also an increasing
number of patients with various immune defects (haematological
malignancies, solid tumours, organ transplantation, immunosup-
pressive treatments, etc.) or underlying conditions (intensive care
unit, indwelling catheter, prosthetic devices, broad spectrum
antibiotics, etc.). This complex setting often prompts use of pre-
emptive, prophylactic and prolonged curative antifungal treat-
ments that can favour the emergence of resistant species or
mutations in the drug target [6]. The azoles are to our knowledge
the only class compounds used both in agriculture and in clinical
medicine. They block the biosynthesis of fungal ergosterol by
inhibition of cytochrome P450 14-alpha demethylase. Derivatives
of piperazines, pyridines and pyrimidines are also used as
fungicides for plant protection and have a mode of action similar
to that of azoles [7].
Knowledge about the yeasts antifungal susceptibility profiles is
limited to species responsible for human infections. During this
study a comprehensive analysis of antifungal susceptibility profiles
of a large number of yeast type strains available at the reference
collection of the Centraalbureau voor Schimmelcultures (CBS,
Utrecht, The Netherlands) were undertaken. Human pathogenic
species as well as species recovered from other sources (e.g.
environment, food and insects) were included in this study.
Antifungal drugs tested belonged to the five known classes of
antifungal drugs (polyenes, azoles, echinocandins, allylamines and
antimetabolites). The aim of this study was to look into the
possibility whether species with decreased susceptibility to one or
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animal health taking also into account their ability to grow at
37uC. We also used our database of 4240 isolates recovered mainly
from clinical specimens and collected at the French National
Reference Center (NRCMA) to compare the antifungal suscepti-
bility of the 53 species shared among the CBS reference strains
and the clinical isolates.
Results
Differences in antifungal susceptibility profiles between
Basidiomycetes and Ascomycetes in the CBS and the
National Reference Center for Mycoses and Antifungals
(NRCMA) collections
A total of 1698 yeast reference strains and 4240 clinical isolates
were studied (Table 1). Table 2 summarizes the antifungal
susceptibility results according to the division for all the reference
strains and the clinical isolates. For the reference strains, geometric
mean minimal inhibitory concentrations (MICs) of all antifungal
drugs tested were significantly higher for Basidiomycetes com-
pared to Ascomycetes (p,0.001, Table 2). Thus, using the
previously defined thresholds, the percentage of reference strains
with resistance or decreased susceptibility to drugs was signifi-
cantly higher for Basidiomycetes than for Ascomycetes (Table 3).
Almost half the Basidiomycetes strains could be considered as
‘‘resistant’’ for flucytosine (5FC) and amphotericin B (AmB) and
even more than half for fluconazole (FCZ), voriconazole (VRZ),
and caspofungin (Caspo). For the Ascomycetes, less than 20% of
the reference strains were considered resistant except for FCZ
(38.3%). There was no visible alteration in antifungal susceptibility
profiles over time for either Basidiomycetes or Ascomycetes (data
not shown). If we arbitrarily define ‘‘resistance’’ for a given class of
antifungal drug by $50% of the strains with decreased
susceptibility to that drug, provided that at least five strains were
tested, 16 of the 38 genera of reference strains of Ascomycetes
tested were ‘‘resistant’’ to at least one class (13 being resistant to
azoles), five genera to two classes (two to azoles/5FC, and one
each to azoles/echinocandin, azoles/polyenes and azoles/allyl-
amines), and one genus, Yarrowia, that has already been described
to be a human opportunistic pathogen, to four classes (Table S1).
For the Basidiomycetes, all strains representatives of the 19 genera
were ‘‘resistant’’ to echinocandins, none was resistant to
allylamine; Fellomyces and Hannaella, that are unknown as human
pathogens, were ‘‘resistant’’ to four classes and the strains tested
belonging to the 11 genera including the known opportunistic
pathogens Trichosporon, Cryptococcus, Pseudozyma and Rhodosporidium
were resistant to three classes (Table S2).
For the clinical isolates, significant differences in geometric
mean MICs were recorded for all drugs between Basidiomycetes
and Ascomycetes except for itraconazole (ITZ, not significantly
different) and terbinafine (Terbi, MICs were higher in Ascomy-
cetes compared to Basidiomycetes, p,0.001) (Table 2).
Comparison of antifungal susceptibility profiles for the
species shared between the collections of CBS reference
strains and NRCMA clinical isolates
The MICs for the 53 different species corresponding to the 4240
clinical isolates collected at the NRCMA were analysed and
compared to those obtained for the corresponding 315 reference
strains (Table 4, Tables S1 and S2). When analysing data for each
species (Tables S3 and S4), the overall distribution of the MICs
(MIC50, MIC90 and MIC ranges) was similar between reference
strains and clinical isolates.
Among the Ascomycetes, the proportion of decreased suscep-
tibility to antifungals was similar between the reference strains and
the clinical isolates for VRZ, posaconazole (PSZ), 5FC, Terbi, and
Caspo. A significant but less than 2-fold difference was observed
for FCZ and ITZ. The proportion of AmB resistance for reference
strains was almost 2-fold more than that recorded for clinical
isolates (Table 4). One Yarrowia lipolytica reference strain and two
clinical isolates of Candida glabrata and Candida krusei, were resistant
to all five classes of antifungal drugs. Major discrepancies were
observed for Candida tropicalis with MIC50 and MIC90 of the
azoles higher for the reference strains than for the clinical isolates
where seven from the12 reference strains were resistant to at least
one azole, including six recovered before 1970 and four from
human samples. None of the C. tropicalis reference strains had 5FC
MIC.8 mg/ml in contrast with almost 33% (103/313) of the
clinical isolates. Some discrepancies in Caspo MICs distribution
were also noted with a few clinical isolates of Candida albicans,
Candida glabrata, Candida rugosa, Candida tropicalis, Clavispora lusitaniae
and Kodamaea ohmeri that exhibited high MICs. Most of these
isolates have been recovered from patients previously exposed to
echinocandins.
Among the Basidiomycetes the percentage of strains with
resistance or decreased susceptibility was drastically higher among
reference strains than among clinical isolates for azoles and Terbi,
and lower for 5FC and AmB. Of the 604 Basidiomycetes tested
(548 clinical isolates and 56 reference strains), only two Cryptococcus
neoformans, one Cryptococcus gattii, one Cryptococcus laurentii and one
Trichosporon inkin had low Caspo MICs, leaving 99% of the
Basidiomycetes resistant to Caspo.
Relationship between thermotolerance, source of
isolation and antifungal drugs susceptibility profile
Among the 1470 reference strains for which the maximum
temperature of growth was determined, 535 (36.4%) were known
to grow at 37uC or above, including 488 Ascomycetes (48 genera
and 227 species) and 47 Basidiomycetes (8 genera and 26 species).
Therefore, the proportion of strains able to grow at 37uC varied
according to the Division (46.3% for the Ascomycetes and 11.3%
for the Basidiomycetes) and also according to their source of
isolation (from 61.6% for strains of human source to 16.7% for
those from soil, Table 5) with no Basidiomycetes that were
recovered from insects were able to grow at 37uC. Among the 535
thermotolerant strains, 271 (50.7%; i.e. 256 Ascomycetes strains
belonging to 177 species in 45 genera; 15 Basidiomycetes strains
belonging to 15 species in eight genera) belonged to species
unknown as human pathogens, or at least not described in articles
available in the NCBI library (http://www.ncbi.nlm.nih.gov/).
The proportion of strains with decreased susceptibility to the
various antifungal drugs varied according to the source of isolation
(humans, other living organisms, food and industrial products,
environment and water): azoles (39614%), 5FC (1168%), Terbi
(1364%), Caspo (23612%) and AmB (2068%) (Table 5). Strains
recovered from insects had the lowest proportion of ‘‘resistance’’
compared to other sources for all antifungals except 5FC (data not
shown). The highest proportion of ‘‘resistance’’ was observed for
strains recovered from drinks (alcoholic beverages, fruit juices, soft
drinks) (with regards to azoles and Terbi resistance), from humans
(5FC), environment and animals (Caspo) and animals (AmB).
When analysing all the reference strains regardless of the
thermotolerance, 24 strains (i.e. 1.5% of the 1580 strains tested
against all antifungal drugs), belonging to 23 different species and
including 19 Basidiomycetes, were resistant to all drugs. The
reported sources were six strains from the environment, five from
soil, six from plants and one from animal and human. Among the
Yeasts and Antifungal Resistance
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(Cryptococcus albidus and Y. lipolytica), and three were recovered from
clinical specimens (Cryptococcus magnus, Bulleromyces albus (CBS
database) and Pseudozyma hubeiensis (NRCMA unpublished data)).
Among the four Ascomycetes isolates resistant to all antifungal
drugs, three were included or related to the Y. lipolytica clade (Y.
lipolytica, Candida hispaniensis and Candida umkomasiana). Among these
24 ‘‘resistant’’ strains, 17 were able to grow at 30uC and only seven
at 37uC. Finally, among the seven resistant species able to grow at
37uC, five were unknown as human pathogen (two Ascomycetes,
C. hispaniensis and Zygosaccharomyces mellis; three Basidiomycetes,
Pseudozyma crassa, Trichosporon lactis and Trichosporon veenhuisii).
Discussion
The limitations of the present study should be kept in mind.
Firstly, antifungal susceptibility testing was not performed for all
strains in identical conditions because of changes in incubation
parameters requested by temperature requirements and slow
growth rate in the test media for some species. This implies also
that not all reference strains of a given genus and/or only a few
strains for a given species were available for analysis. Secondly,
storage of the reference strains was uneven considering time
period, geographical zone and source of isolation, thus preventing
definitive conclusions regarding evolution of drug resistance over
time or according to substrates. Furthermore, the proportion of
Ascomycetes versus Basidiomycetes from the various substrates for
the reference strains does not reflect the reality in terms of overall
species’ diversity, colonization, saprophitism or pathogenicity.
Finally, future changes in taxonomy may alter some of our
conclusions that are based on our current knowledge on specific
genera or species.
The first striking result of this study was the higher proportion of
strains with decreased susceptibility, regardless of the class of
antifungal drugs used, among Basidiomycetes compared to
Ascomycetes reference strains. The drastic difference observed
for echinocandins (92% Basidiomycetes and 13% Ascomycetes
reference strains with Caspo MIC$0.5 mg/ml) is well known for
pathogenic species, and was confirmed by comparison with the
clinical isolates. Caspofungin is one of the three antifungal agents
Table 1. Description of the reference strains and the clinical isolates studied.
Reference strains Clinical isolates
Ascomycetes Basidiomycetes Total Ascomycetes Basidiomycetes Total
Number of
strains 1209 489 1698 3557 683 4240
genera 71 48 119 19 5 23
No. of strains per genus 1–385 1–90
No. of species per genus 1–257 1–70
species 634 358 993 43 10 53
No. of strains per species 1–30 1–29
Site of isolation or substrate
Human 125 52 177 3489 679 4168
Living organisms 503 246 749 3 3 6
Water 24 29 53
Environment 185 101 286 6 0 6
Food & industrial products 292 19 311
unknown 80 42 122 59 1 60
Geograpical area* 994 419 1413
Europe 354 124 478 3493 630 4123
Africa 103 18 121 8 6 14
North America 171 27 198
South America 138 26 164 55 47 102
Asia 195 177 372
Oceania 27 21 48 1 0 1
Antartica 62 6 3 2
Period of isolation* 1193 481 1674
1905–1958 490 109 599
1959–1972 262 84 346
1973–1990 184 101 285
1991–1995 24 24 48
1996–2000 89 41 130
2001–2009 144 122 266 3557 683 4240
*when information is available.
doi:10.1371/journal.pone.0032278.t001
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the synthetic cell-wall enzyme complex beta-1,3D-glucansynthase
[8]. Filobasidiella neoformans had a hotspot region in beta-1,3D-
glucansynthase similar to that of the susceptible Ascomycetes
species C. albicans and Saccharomyces cerevisiae but is intrinsically
resistant to echinocandins. A previous study has already shown the
presence of fks1-like genes in ten species of Basidiomycetes with
sequences remarkably similar to Fks1 from F. neoformans [9]. This
difference in echinocandins susceptibility between Ascomycetes
and Basidiomycetes could be the result of phylogenetic differen-
tiation of the cell-wall composition with potential modification of
the three-dimensional structure of the betaglucan synthase
complex that remains to be analyzed.
Almost all (84%) of the genera of Basidiomycetes included more
than 50% of reference strains with decreased susceptibility to
azoles compared to 34% of the genera of Ascomycetes. Most
(68%) genera of Basidiomycetes included more than 50%
of the reference strains with decreased susceptibility to at least
three classes compared to the Ascomycetes genera (3%). The fact
that the resistance profiles of the reference strains were not
associated with a specific substrate or period corresponding to
specific drug launching time suggest that it may not have
been acquired through environmental pressure but rather
through recombination or other evolutionary processes. A
comprehensive analysis of the target genes is necessary to validate
this hypothesis.
Table 2. Distribution of MICs according to the phylum of clinical isolates and reference strains.
Ascomycetes Basidiomycetes
No. isolates GeometricMean
MIC50/MIC90
(mg/mL) Range (mg/mL)
No.
isolates GeometricMean
MIC50/MIC90
(mg/mL)
Range (mg/
mL)
Type strains
Fluconazole 1147 3.38 4/32 0.12–128 445 14.24 16/128 0.12–128
Voriconazole 1147 0.06 0.06/0.5 0.015–16 445 0.24 0.25/4 0.015–16
Itraconazole 1147 0.08 0.06/0.05 0.015–16 445 0.20 0.12/16 0.015–16
Posaconazole 1147 0.10 0.12/0.5 0.015–16 445 0.22 0.25/2 0.015–16
Flucytosine 1147 0.26 0.12/2 0.12–128 445 4.82 4/128 0.12–128
Terbinafine 1147 0.84 1/8 0.015–16 445 1.30 2/8 0.015–16
Caspofungin 1202 0.09 0.06/0.5 0.015–16 484 4.36 8/16 0.015–16
Amphotericin B 1202 0.06 0.06/0.25 0.015–16 484 0.15 0.12/0.5 0.015–16
Clinical isolates
Fluconazole 3550 0.98 0.5/32 0.12–128 683 3.90 4/16 0.12–128
Voriconazole 3550 0.04 0.015/0.5 0.015–16 683 0.05 0.06/0.12 0.015–16
Itraconazole 2206 0.07 0.03/1 0.015–16 427 0.06 0.06/0.25 0.015–4
Posaconazole 3547 0.07 0.06/1 0.015–16 683 0.10 0.12/0.25 0.015–16
Flucytosine 3550 0.24 0.12/1 0.12–128 683 4.17 4/16 0.12–128
Terbinafine 2157 1.27 2/8 0.015–16 420 0.73 1/2 0.03–16
Caspofungin 2998 0.06 0.06/0.25 0.015–8 548 3.9 8/8 0.12–8
Amphotericin B 3556 0.08 0.06/0.25 0.015–4 682 0.18 0.12/0.5 0.015–16
doi:10.1371/journal.pone.0032278.t002
Table 3. Proportion of reference strains with high MIC.
N6 of isolates with high MIC* to the corresponding
antifungal (%) Ascomycetes Basidiomycetes p
Fluconazole $8 mg/mL 439/1147 (38.3) 302/445 (67.9) ,0.001
Voriconazole $0.25 mg/mL 236/1147 (20.6) 231/445 (51.9) ,0.001
Itraconazole $0.5 mg/mL 161/1147 (14.0) 144/445 (32.4) ,0.001
Posaconazole $0.5 mg/mL 155/1147 (13.5) 149/445 (33.5) ,0.001
Flucytosine $8 mg/mL 78/1147 (6.8) 219/445 (49.2) ,0.001
Terbinafine $8 mg/mL 143/1147 (12.5) 80/445 (18.0) 0.006
Caspofungin $0.5 mg/mL 154/1202 (12.8) 445/484 (91.9) ,0.001
Amphotericin B $0.25 mg/mL 168/1202 (14.0) 214/484 (44.2) ,0.001
Amphotericin B $1 mg/mL 25/1202 (2.1) 44/484 (9.1) ,0.001
*Minimal inhibitory concentration.
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reference strains with the clinical isolates belonging to shared
species showed that the profiles were similar except for a few
species. Indeed, some Candida spp. clinical isolates with high Caspo
MIC were recovered from patients previously exposed to Caspo
(acquisition of resistance by nonsense mutation in hotspot regions
of the betaglucan synthase [10,11,12,13]), whereas reference
strains of C. albicans, C. glabrata, C. rugosa, C. tropicalis, C. lusitaniae
and K. ohmeri recovered before Caspo usage had low MICs. None
of the C. tropicalis type strains had 5FC MIC.8 mg/ml in contrast
with almost 33% of the clinical isolates. It was previously showed
that most of these clinical isolates belong to a single 5FC-resistant
clone [14]. The widespread use of antifungal drugs especially
azoles since the 1970s in agriculture (http://www.pesticides.gov.
uk/rags.asp?id=644) may also contribute to the emergence of
resistance. The drugs are used repeatedly over a long period of
time and could thereby create a persistent pressure of azole
compounds on saprophytic fungi [15]. Indeed, resistance of
clinical isolates of Aspergillus spp. to azoles has been shown to occur
in patients treated with voriconazole but also following environ-
mental exposure of the infecting isolates [13,16]. However, there is
no obvious explanation for the high proportion of C. tropicalis
reference strains with high azoles MICs compared to very few
clinical isolates since only three were recovered after 1970.
However, the overall similarity of the results between reference
strains and clinical isolates, suggests that the results obtained with
the other reference strains could be valid.
Robert and Casadevall suggested in their study of fungal
thermotolerance that ‘‘new human pathogenic fungi are likely to
emerge from genera that are already tolerant to higher
temperatures’’ [17]. Among the 1698 reference strains studied,
535 strains from 253 species were able to grow at human body
temperature, among which several species (177/634 Ascomycetes
species and 15/358 Basidiomycetes species) were unknown as
human opportunistic pathogens. Keeping in mind that growth
limitation evidenced in vitro could be related to culture medium or
conditions and could not apply in vivo, it was found that five of the
seven species were resistant to all antifungal classes and able to
grow at 37uC were unknown as human pathogen. Even though
the in vitro/in vivo correlation was not demonstrated, knowing the in
vitro susceptibility to systemic antifungal agents and the putative
intrinsic resistance of these thermotolerant species is important as
they could become opportunistic human pathogens. As an
example, the species Y. lipolytica has been studied for its
biotechnological importance [18] but is also known to be
responsible for human invasive infections mainly in immunocom-
promised patients. Interestingly, among the six species belonging
to the Y. lipolytica clade [19], the two species Y. lipolytica and C.
hispaniensis, both able to grow at 37uC, include two reference
strains with high MICs for all antifungals. Candida hispaniensis,
Table 4. Comparison of reference strains and clinical isolates with high MIC.
Ascomycetes Basidiomycetes
No. isolates with MIC* to the
corresponding antifungal type strains %
clinical
isolates % p type strains %
clinical
isolates % p
Fluconazole $8 mg/mL 87/258 33.7 848/3550 23.9 0.001 41/55 74.6 236/683 34.6 ,0.001
Voriconazole $0.25 mg/mL 48/258 18.6 693/3550 19.5 0.745 41/55 74.6 48/683 7.0 ,0.001
Itraconazole $0.5 mg/mL 42/258 16.3 447/2206 20.3 ,0.001 37/55 76.3 22/427 5.2 ,0.001
Posaconazole $0.5 mg/mL 46/258 17.8 624/3547 17.6 0.933 34/55 61.8 59/683 8.6 ,0.001
Flucytosine $8 mg/mL 15/258 5.8 184/3550 5.2 0.775 11/55 20 249/683 36.5 0.013
Terbinafine $8 mg/mL 42/258 16.3 313/2157 14.5 0.457 24/55 43.6 10/420 2.4 ,0.001
Caspofungin $0.5 mg/mL 18/259 7 277/2898 9.6 0.182 53/56 94.6 546/548 99.6 0.007
Amphotericin B $0.25 mg/mL 53/259 20.5 399/3556 11.2 ,0.001 20/56 35.7 337/682 49.4 0.052
*Minimum Inhibitory Concentration.
doi:10.1371/journal.pone.0032278.t004
Table 5. Reference strains able to grow at 37uC with high MIC according to source of isolation.
Percent of strains with decreased susceptibility to
Source of isolation
No. strains able
to grow at 376C/
No. strains
No. Strains
Tested in
RPMI Fluco Vori Itra Posa 5FC Terbi
No.
Strains
Tested in
AM3 Caspo AmB
Human 109/177 109 28% 20% 12% 10% 16% 11% 109 21% 17%
Living organisms 188/749 183 32% 20% 13% 11% 9% 9% 188 15% 17%
Environment 58/286 56 45% 21% 18% 16% 5% 16% 58 17% 17%
Water 9/53 9 0% 11% 11% 0% 22% 11% 9 44% 33%
Food & Industrial products 140/311 130 50% 25% 23% 25% 4% 19% 140 16% 19%
All (mean ± SD) 504/1556 487 31620 19651 5 651 2 691 1 681 3 645 0 4 2 3 612 2068
doi:10.1371/journal.pone.0032278.t005
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opportunist. Furthermore, among the Y. lipolytica clade, Candida
bentonensis, able to grow at 35uC, had high MICs for all antifungals
except 5FC. Candida galli, previously described in chicken
infections, and unable to grow above 35uC, had high MICs for
5FC, Fluco, Vori and AmB. The other species of the clade, Candida
uncommunis and Aciculoconidium aculeatum were unable to grow above
35uC and 30uC respectively and had high MICs for AmB. Of
note, the isolate of the species C. umkomasiana, previously identified
as Y. lipolytica was also resistant to all antifungal drugs. The
genomic study of species present in the Y. lipolytica clade and of
additional closely related species could therefore be particularly
interesting in terms of multidrug resistance.
In conclusion, this study provides the first comprehensive
analysis of antifungal susceptibility profiles for almost 1700
reference strains representing more than 119 genera and 993
species. It paves the way to further phylogenetic studies on the
origin of drug resistance and evolution in Basidiomycetes and
Ascomycetes. It also shows that species with high levels of
resistance can be found in the environment without previous
environment drug pressure and could become opportunistic
human pathogens. Finally, it underlines how important correct
identification of species is, especially for uncommon species,
pointing out the need for reliable fungal sequence databases [20].
Materials and Methods
Yeasts Type Strains
A total of 1698 yeast reference strains available from the CBS
collection, that include type strains (T), authentic strains (AUT),
syntypes (ST), lectotypes (LT), IT (isotype), AT (allotype) or
neotypes (NT) of currently accepted species and also from
previously described species that are now considered to be
synonyms of the accepted species, were studied. The strains
belonged to the Division of Ascomycota (71.2%, 71 genera, 634
species) and Basidiomycota (28.8%, 48 genera, 358 species)
(Table 1). Strains were recovered from various sources, such as
plants (27.7%), soil (12.4%), drinks (10.7%), insects (10.6%) and
humans (10.4%) (Table 1). The geographical areas of isolation
were diverse, but most strains were isolated from Europe (33.8%)
and Asia (26.3%) for the 1413 isolates for which the information
was available. The oldest isolate was found in 1905, but 43.5% of
the strains were recovered since 1973 and 15.9% since 2001.
All strains were stored in lyophilised form at the CBS. They
were subcultured at least twice on Sabouraud agar plates (GibcoH,
Invitrogen
TM, Life Technologies, CA, USA) before in vitro
susceptibility testing.
Clinical isolates
The NRCMA received clinical isolates from short-stay univer-
sity hospital laboratories. These isolates are part of surveillance
programs or send to the NRCMA due to difficulties during the
identification process. The isolates corresponding to species for
which a reference strain was available were included in the
analysis (n=4240) (Table 1). They belonged to the Ascomycota
(83.9%, 19 genera and 43 species) and Basidiomycota (16.1%, five
genera, ten species). Five species encompass 86.3% of the clinical
isolates (Candida albicans (40.9%), Cryptococcus neoformans (14.9%),
Candida glabrata (14.5%), Candida parapsilosis (8.6%) and Candida
tropicalis (7.4%)). Isolates were mainly recovered from humans
(83.7%) in Europe (84.7%) and all between January 2003 and July
2010.
Upon receipt, all isolates were identified by phenotypic methods
(urease activity, Urea-Indole, bioMe ´rieux, Marcy l’Etoile, France;
carbon assimilation profiles, ID32C, bioMe ´rieux), and by
sequencing of the ITS and D1/D2 regions of the gene coding
for ribosomal RNA by using universal primers (V9D/LS266 and
NL1/NL4 primers, respectively [21,22,23,24]). Candida albicans
was differentiated from Candida dubliniensis by amplification of a
portion of the gene coding for actin [25]. MICs of various systemic
antifungal drugs (see below) were determined on a routine basis for
each isolate.
In vitro susceptibility testing
In vitro susceptibility was determined by a microdilution
technique following the procedure proposed by the Antifungal
Susceptibility Testing Subcommittee of EUCAST (AFST-EU-
CAST [26]) with modifications of the temperatures and duration
of incubation when necessary.
Active powder of known potency of flucytosine (5FC, Sigma,
Saint Quentin Fallavier, France), fluconazole (FCZ, Pfizer Inc.,
Groton, CT, USA), itraconazole (ITZ, Janssen-Cilag, Issy-les-
Moulineaux, France), voriconazole (VRZ, Pfizer), posaconazole
(PSZ, Merck and Co., Rahway, New Jersey, USA), terbinafin
(Terbi, Novartis Pharma AF, Basel, Schwitzerland), caspofungin
(Caspo, Merck) and amphotericin B (AmB, Sigma Chemicals) were
used. Stock solutions were prepared in sterile distilled water (5FC,
FCZ, Caspo, Terbi) or DMSO (AmB, ITZ, VRZ, PSZ) and stored
at 280uC until used. Stock solutions were diluted in RPMI 1640
(Sigma) buffered to pH 7.0 with 0.165 M morpholinepropanesul-
fonic acid (MOPS, Sigma) for all antifungals except Caspo and
AmB that were diluted in AM3 medium (Difco
TM, Becton-
Dickinson, Le Pont de Claix, France). Final concentrations ranged
from 0.125 to 64 mg/ml (5FC and FCZ) and from 0.015 to 8 mg/ml
(for the others). Both media were supplemented with glucose (final
concentration 2%). Microplates (96 wells flat-bottom, TPPH,
Switzerland) were prepared by batches and stored frozen at
220uC for less than 6 months. The following reference strains
were included as quality controls: C. parapsilosis ATCC 22019 and
Pichia kudriavzevii (synonym of Issatchenkia orientalis, teleomorph of
Candida krusei [27]) ATCC6258. Fungal growth was determined by
anautomated microplatereaderspectrophotometer(MultiscanRC-
351,LabsystemsOy,Helsinki,Finland)at492 nmafteratleast24 h
of incubation and/or until absorbance of the drug-free well was
$0.2. The MIC was defined as a 50% (90% for amphotericin B) or
more reduction in growth compared to the drug-free well.
For the reference strains, a few parameters had to be changed
because the procedure is standardized for glucose fermentative
yeasts able to grow at 35uC. Thus, growth temperature for the
subculture and subsequent incubation of the microplates was
changed for the majority of the strains (30uC, 20uC and 15uC for
1503, 158, and 17 strains, respectively). Incubation time varied,
24 hrs for 713 (42%), 48 hrs for 466 (27%), 72 hrs for 232 (14%),
4 days for 145 (8.5%), 6 days for 121 (7%), 7 days for 21 (1%)
strains. Likewise, the test medium did not allow sufficient growth
and thus determination of the MIC for some strains was limited to
azoles, 5FC and Terbi or Caspo and AmB (106 missing values for
drugs tested in RPMI and 12 for drugs tested in AM3).
Resistance to FCZ and VRZ were defined as a MIC higher than
or equal to 8 and 0.25 mg/mL, respectively according to EUCAST
recommendations [26]. Decreased susceptibility to 5FC and Caspo
were arbitrarily defined by a MIC higher than or equal to 8 and
0.5 mg/mL, respectively according to previous data obtained in the
laboratory showing that clinical isolates of Candida spp. exhibiting
MICs above these thresholds harboured mutations in target genes
[28,29]. We defined arbitrary thresholds for ITZ, PSZ, AmB and
Terbi by determining the MIC that inhibited at least 90% of the
clinicalisolates.This correspondedtoa MIChigherthanorequalto
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mL for Terbi. The values corresponding to the concentration
inhibiting 50% (MIC50) or 90% (MIC90) of the strains were
calculated for species including more than ten strains.
Statistical analysis
Data were analyzed using Stata
TM (version 10.1, College
Station, TX, USA). Distribution of MICs between Ascomycetes
and Basidiomycetes were compared using the non-parametric
Kruskall Wallis test. Comparisons between groups were done
using Chi Square or Fisher exact tests for the proportions of
strains/isolates with decreased susceptibility to a drug. A p-value of
,0.05 was considered statistically significant.
Supporting Information
Table S1 Percentage of isolates with high MIC within genera in
the Ascomycota phylum.
(XLS)
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